biotechnolgy
All Coverage
STAT Plus: Former Merck CEO: Democracy and the drug industry are both in danger
STAT Plus: This billionaire has quietly driven Boston’s biotech industry for decades
STAT Plus: European researchers seek greater stake in drug development in bid to improve access
STAT Plus: Bristol Myers Squibb to buy Turning Point Therapeutics for $4.1 billion to gain drugs targeting rare cancer mutations
STAT Plus: Bayer to pay CRISPR-focused Mammoth Biosciences $40 million for gene editing research
